Chris Viehbacher, Biogen CEO (Suzanne Kreiter/The Boston Globe via Getty Images)
Biogen cuts almost one-third of Reata's staff following $7B buyout
Biogen made a big M&A splash in July with its $7.3 billion buyout of Reata Pharmaceuticals, which had just secured FDA approval for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
